Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares

Posted by Adam Masters on Jan 17th, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00. Following the sale, the president now directly owns 2,911,138 shares of the company’s stock, valued at $31,585,847.30. This represents a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Songjiang Ma also recently made the following trade(s):

On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.10, for a total value of $565.60.
On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $10,591.14.
On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total transaction of $9,560.56.
On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.40, for a total transaction of $24,800.00.
On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.50, for a total transaction of $25,000.00.
On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total value of $25,400.00.
On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.27, for a total value of $24,540.00.
On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total value of $21,640.00.
On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Trading Down 1.2 %

Gyre Therapeutics stock opened at $10.80 on Friday. Gyre Therapeutics, Inc. has a twelve month low of $8.26 and a twelve month high of $26.37. The company has a 50 day moving average of $11.74 and a 200-day moving average of $12.65.

Hedge Funds Weigh In On Gyre Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its position in Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after buying an additional 90,557 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Gyre Therapeutics by 16.9% in the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after purchasing an additional 43,840 shares in the last quarter. Advantage Alpha Capital Partners LP acquired a new position in Gyre Therapeutics during the third quarter worth $334,000. WINTON GROUP Ltd bought a new position in Gyre Therapeutics in the second quarter valued at $220,000. Finally, Bank of New York Mellon Corp acquired a new stake in Gyre Therapeutics in the 2nd quarter valued at $218,000. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.